CN100339081C - Oral loratadine disintegrating tablet and its prepn - Google Patents
Oral loratadine disintegrating tablet and its prepn Download PDFInfo
- Publication number
- CN100339081C CN100339081C CNB2004100679894A CN200410067989A CN100339081C CN 100339081 C CN100339081 C CN 100339081C CN B2004100679894 A CNB2004100679894 A CN B2004100679894A CN 200410067989 A CN200410067989 A CN 200410067989A CN 100339081 C CN100339081 C CN 100339081C
- Authority
- CN
- China
- Prior art keywords
- loratadine
- disintegrating tablet
- tablets
- oral
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960003088 loratadine Drugs 0.000 title claims abstract description 35
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000000945 filler Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 235000012239 silicon dioxide Nutrition 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 230000000149 penetrating effect Effects 0.000 claims description 6
- 150000005846 sugar alcohols Polymers 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 235000019890 Amylum Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 239000003651 drinking water Substances 0.000 abstract description 2
- 235000020188 drinking water Nutrition 0.000 abstract description 2
- 238000010579 first pass effect Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 3
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract 3
- 229920005862 polyol Polymers 0.000 abstract 2
- 150000003077 polyols Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 210000002200 mouth mucosa Anatomy 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 230000002052 anaphylactic effect Effects 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属医药领域，具体涉及一种治疗过敏性疾病的氯雷他定口腔崩解片及其制备方法，氯雷他定口腔崩解片剂，包括药物活性成分氯雷他定和赋形剂的混合物，其特征在于所述的赋形剂包括崩解剂、填充剂、可溶性多元醇和渗透剂；该片剂中各组分的重量比为：氯雷他定20%～50%、崩解剂5%～15%、填充剂10%～30%、可溶性多元醇30%～60%、渗透剂1%～5%。本发明与普通口服制剂相比，因胃肠道粘膜被速崩后的药物广泛覆盖，起效迅速。而且药物可以通过口腔粘膜吸收，免去了首过效应，提高了生物利用度，减少了对胃肠道的刺激。由于口腔崩解片在口内不需水即可服下，为饮水不便的人们口服用药提供了方便。The invention belongs to the field of medicine, and in particular relates to a loratadine orally disintegrating tablet for treating allergic diseases and a preparation method thereof. The loratadine orally disintegrating tablet includes a pharmaceutical active ingredient loratadine and excipients The mixture is characterized in that the excipients include disintegrants, fillers, soluble polyols and penetrants; the weight ratio of each component in the tablet is: loratadine 20% to 50%, disintegration Agent 5%~15%, filler 10%~30%, soluble polyol 30%~60%, penetrant 1%~5%. Compared with common oral preparations, the present invention has rapid onset of effect because the gastrointestinal tract mucosa is widely covered by rapidly disintegrating medicines. Moreover, the drug can be absorbed through the oral mucosa, eliminating the first-pass effect, improving bioavailability, and reducing irritation to the gastrointestinal tract. Because the orally disintegrating tablet can be taken in the mouth without water, it provides convenience for people who have inconvenient drinking water to take medication orally.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of preparation method for the treatment of the oral loratadine disintegrating tablet of anaphylactic disease.
Background technology
Anaphylaxis be a kind of acute, general, seriously arrive even life-threatening allergy, take place when before the patient, being contacted same allergen once more after certain allergen sensitization.Anaphylactoid symptom can occur behind the contact allergen immediately or in 2 hours.The patient does not feel like oneself, agitation, cardiopalmus, tremble, erubescence is itched, tinnitus, cough, sneeze, urticaria, edema or because of asthma and airway obstruction cause dyspnea, and cardiovascular system depletion can take place under the situation that Respiratory symptoms do not occur.The symptom that when anaphylaxis takes place, may occur cardiovascular or respiratory system usually, but anaphylactoid people repeatedly takes place in the appearance simultaneously of the symptom of two kinds of systems, and the symptom when at every turn showing effect is usually similar.Anaphylactoid process is very fast, can cause collapse, tic, urinary incontinence, loss of consciousness very soon, apoplexy occurs in 1～2 minute.Unless carry out emergency treatment immediately, otherwise anaphylaxis usually causes death.
Anaphylaxis can be caused by various allergens.Anaphylaxis can not take place when contacting allergen for the first time, contact then may take place once more.But when for the first time most of people also do not know contacted certain allergen.
Loratadine is the of new generation long-acting three ring antihistaminics of a kind of long-acting, no sedation, no anticholinergic effect, has the effect of selectivity antagonism periphery H1-receptor.In the therapeutic dose scope, do not have drowsiness effect, be applicable to shed tears, sneeze, allergic rhinitis, acute or chronic urticaria disease and other anaphylaxis dermatosis.Ethanol there is not invigoration effect.Effect rapidly, taking medicine begins onset in back 30 minutes, can not pass through blood brain barrier.
Loratadine is white or off-white color crystalline powder; Almost odorless is tasteless.Atomic molten in water or ethanol, insoluble in ether or chloroform; In alkaline solution, dissolve.Present loratadine generally all is oral gastric solubility preparation, and medicine can not be absorbed rapidly, and onset is slower, and takes inconvenience, especially for because of the bad patient of anaphylactic disease function of deglutition.
Summary of the invention
The objective of the invention is to overcome the defective that exists in the background technology, provide a kind of rapid-action, bioavailability is high, the preparation method of the oral loratadine disintegrating tablet of taking convenience.
A kind of preparation method of oral loratadine disintegrating tablet, oral loratadine disintegrating tablet comprise the mixture of active constituents of medicine loratadine and excipient, and described excipient comprises disintegrating agent, filler, solubility polyhydric alcohol and penetrating agent; The weight ratio of each component is in this tablet: loratadine 20%～50%, disintegrating agent 5%～15%, filler 10%～30%, solubility polyhydric alcohol 30%～60%, penetrating agent 1%～5%; Described disintegrating agent is a crospovidone, one or more mixing in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, the carboxymethyl starch sodium; Described filler is one or more mixing in pregelatinized Starch, amylum pregelatinisatum, lactose, sucrose and glucose, cellulose and microcrystalline Cellulose, the gelatin; Described solubility polyhydric alcohol is one or more mixing in mannitol, xylitol, Sorbitol and the maltose alcohol; Described penetrating agent is for having the silicon dioxide of high-affinity, one or more mixing in the maltodextrin to water; The main processing step of this method is as follows: mix by the component prescription, prepare tablet with powder pressing method or freeze-drying.
Above-mentioned tablet can also comprise one or more in the lubricant of 0.5%～3% essence, 0.5%～3% sweeting agent and 0.5%～1.5%.
In the above-mentioned method, use loratadine 250g, mannitol 420g, microcrystalline Cellulose 150g, crospovidone 70g and an amount of essence, sweeting agent and lubricant when preparing 1000 tablets of tablets.
In the above-mentioned method, use loratadine 250g, sorbitol 400g, glucose 80g, sucrose 70g, cross-linking sodium carboxymethyl cellulose 60g, silicon dioxide 20g and an amount of essence, sweeting agent and lubricant when preparing 1000 tablets of tablets.
In the above-mentioned method, use loratadine 250g, mannitol 200g, sucrose 220g gelatin 50g, hydroxyethyl-cellulose 40g and an amount of essence when preparing 1000 tablets of tablets.
The oral cavity disintegration tablet of method preparation of the present invention is compared with common oral preparation, is extensively covered by the medicine after fast the collapsing because of gastrointestinal tract mucous, and onset is rapid.And medicine can the through port transmucosal absorbs, and removed first pass effect from, improved bioavailability, and having reduced stimulates gastrointestinal.For the anaphylactic disease patient provides a kind of new dosage form that makes things convenient for.Because oral cavity disintegration tablet does not need in mouth under water can obey, for people's oral medication of the inconvenience of drinking water provides convenience.
This tablet is to produce disintegrate, generally disintegrate in less than 40 seconds, or even disintegrate in less than 30 seconds when contacting with saliva in the oral cavity.The oral cavity disintegration tablet that provides among the present invention has better hardness, both can be convenient to packing and transportation, is convenient to suitability for industrialized production again.
The specific embodiment
We never are limited to this from the further illustrated in greater detail the present invention of the following example but should understand scope of the present invention.
Embodiment 1: 1000 oral loratadine disintegrating tablets of present embodiment preparation (specification: 0.25g), use following compositions:
The name of material inventory
Loratadine 250g
Mannitol 420g
Microcrystalline Cellulose 150g
Crospovidone 70g
Aspartame 20g
Herba Menthae essence 10g
Silicon dioxide 20g
Magnesium stearate 5g
Processing step: raw material, granules of accessories add aspartame, Herba Menthae essence and silicon dioxide, magnesium stearate, mix homogeneously, tabletting, packing.
Sample to above-mentioned prescription carries out mouthfeel, Orally disintegrating time, disintegration, friability mensuration.
Test item
Mouthfeel is good
28 seconds Orally disintegrating time limits
19 seconds disintegrations
Friability 0.5%
Embodiment 2: 1000 oral loratadine disintegrating tablets of present embodiment preparation (specification: 0.25g), use following compositions:
The name of material inventory
Loratadine 250g
Sorbitol 400g
Glucose 80
Sucrose 70g
Cross-linking sodium carboxymethyl cellulose 60g
Stevioside 25g
Orange flavor 10g
Titanium dioxide 20g
Sodium stearyl fumarate 5g
Processing step: raw material, granules of accessories add stevioside, orange flavor and silicon dioxide, sodium stearyl fumarate, mix homogeneously, tabletting, packing.
Sample to above-mentioned prescription carries out mouthfeel, Orally disintegrating time, disintegration, friability mensuration.
Test item
Mouthfeel is good
25 seconds Orally disintegrating time limits
16 seconds disintegrations
Friability 0.6%
Embodiment 3: 1000 oral loratadine disintegrating tablets of present embodiment preparation (specification: 0.25g), use following compositions:
The name of material inventory
Loratadine 250g
Mannitol 200g
Sucrose 220g
Gelatin 50g
Hydroxyethyl-cellulose 40g
Herba Menthae essence 10g
Processing step: raw material, adjuvant water dissolution, fully mixing joins and is positioned over sharp freezing in the freeze dryer in the mould, is evacuated to dry materials, packs.
Sample to above-mentioned prescription carries out mouthfeel, Orally disintegrating time, disintegration time mensuration.
Test item
Mouthfeel is good
19 seconds Orally disintegrating time limits
14 seconds disintegrations
Claims (5)
1. the preparation method of an oral loratadine disintegrating tablet, oral loratadine disintegrating tablet comprises the mixture of active constituents of medicine loratadine and excipient, it is characterized in that described excipient comprises disintegrating agent, filler, solubility polyhydric alcohol and penetrating agent; The weight ratio of each component is in this tablet: loratadine 20%～50%, disintegrating agent 5%～15%, filler 10%～30%, solubility polyhydric alcohol 30%～60%, penetrating agent 1%～5%; Described disintegrating agent is a crospovidone, one or more mixing in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, the carboxymethyl starch sodium; Described filler is one or more mixing in pregelatinized Starch, amylum pregelatinisatum, lactose, sucrose and glucose, cellulose and microcrystalline Cellulose, the gelatin; Described solubility polyhydric alcohol is one or more mixing in mannitol, xylitol, Sorbitol and the maltose alcohol; Described penetrating agent is for having the silicon dioxide of high-affinity, one or more mixing in the maltodextrin to water; The main processing step of this method is as follows: mix by the component prescription, prepare tablet with powder pressing method or freeze-drying.
2. the preparation method of a kind of oral loratadine disintegrating tablet according to claim 1 is characterized in that also comprising in the lubricant of 0.5%～3% essence, 0.5%～3% sweeting agent and 0.5%～1.5% one or more.
3. the preparation method of a kind of oral loratadine disintegrating tablet according to claim 2 is used loratadine 250g, mannitol 420g, microcrystalline Cellulose 150g, crospovidone 70g and an amount of essence, sweeting agent and lubricant when it is characterized in that preparing 1000 tablets of tablets.
4. the preparation method of a kind of oral loratadine disintegrating tablet according to claim 2 is used loratadine 250g, sorbitol 400g, glucose 80g, sucrose 70g, cross-linking sodium carboxymethyl cellulose 60g, silicon dioxide 20g and an amount of essence, sweeting agent and lubricant when it is characterized in that preparing 1000 tablets of tablets.
5. the preparation method of a kind of oral loratadine disintegrating tablet according to claim 2 is used loratadine 250g, mannitol 200g, sucrose 220g gelatin 50g, hydroxyethyl-cellulose 40g and an amount of essence when it is characterized in that preparing 1000 tablets of tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100679894A CN100339081C (en) | 2004-11-10 | 2004-11-10 | Oral loratadine disintegrating tablet and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100679894A CN100339081C (en) | 2004-11-10 | 2004-11-10 | Oral loratadine disintegrating tablet and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1739513A CN1739513A (en) | 2006-03-01 |
| CN100339081C true CN100339081C (en) | 2007-09-26 |
Family
ID=36092138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100679894A Expired - Lifetime CN100339081C (en) | 2004-11-10 | 2004-11-10 | Oral loratadine disintegrating tablet and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100339081C (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100463674C (en) * | 2006-12-22 | 2009-02-25 | 江苏奥赛康药业有限公司 | Oral cavity quick dissolved film containing civeran, and method for preparing the same |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| HUE041370T2 (en) | 2008-05-21 | 2019-05-28 | Ferring Bv | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
| CN102048682B (en) * | 2009-10-31 | 2012-09-12 | 鲁南制药集团股份有限公司 | Loratadine cream and application thereof |
| AU2011234637B2 (en) * | 2010-03-29 | 2013-08-29 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| JO3112B1 (en) * | 2010-03-29 | 2017-09-20 | Ferring Bv | A fast dissolving pharmaceutical composition |
| CN107648191B (en) * | 2017-09-27 | 2018-08-17 | 扬子江药业集团上海海尼药业有限公司 | A kind of loratadine tablet and its preparation process |
| CN111249239B (en) * | 2020-01-17 | 2022-02-11 | 中国药科大学 | A kind of loratadine nanocrystal and preparation method thereof |
| CN115702935B (en) * | 2021-08-10 | 2024-08-09 | 苏中药业集团股份有限公司 | Loratadine pharmaceutical composition and preparation method thereof |
-
2004
- 2004-11-10 CN CNB2004100679894A patent/CN100339081C/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| 口腔崩释片研制简介 李先何等，实用中西医结合临床，第3卷第2期 2003 * |
| 口腔速崩片拓的研究进展 马萍，中国药师，第7卷第3期 2004 * |
| 口腔速释片的进展及前景 刘梅等，中国药学杂志，第36卷第9期 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1739513A (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100339081C (en) | Oral loratadine disintegrating tablet and its prepn | |
| CA2870130A1 (en) | Compositions and methods for treating cough | |
| JP2008285434A (en) | Orally disintegrating tablets | |
| JP2013533881A (en) | Pharmaceutical composition containing vanoxerin | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| US9107921B2 (en) | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers | |
| CN1302772C (en) | Orally disintegrated sodium ferulate tablet and its prepn process | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN1506043A (en) | Quickly disintegrating tablet containing cadotril | |
| CN101797235B (en) | Oral disintegrating tablet of sodium carbosulfonate and preparation method thereof | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
| CN1270721C (en) | Rapid disintegration and rapid dissolution tablet containing kakonein | |
| CN100394914C (en) | A kind of asarone orally disintegrating tablet and preparation method thereof | |
| CN1830442A (en) | Compound formula dextro methaphen oral disintegration tablet and its preparation method | |
| WO2004082664A1 (en) | Water-soluble tablets of metformin | |
| CN1771920A (en) | Oral disintegrated sertraline tablet and its prepn | |
| CN1321645C (en) | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor | |
| CN101627972A (en) | Entecavir orally disintegrating tablet and method for preparing same | |
| CN119970735A (en) | A compound analgesic drug composition and its application | |
| CN104013590A (en) | Acarbose-containing medicinal composition and preparation method thereof | |
| CN113440492A (en) | Composition of muscarinic receptor antagonist and preparation method thereof | |
| CN102614159B (en) | Ambroxol hydrochloride composition | |
| CN1250217C (en) | Bifendate oral disintegration tablet and its preparing process | |
| Karemore et al. | FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF AN ANTIDIABETIC DRUG |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAINAN POLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN MINHUA Effective date: 20100707 Owner name: ZHEJIANG RUIDA PHARMACEUTICAL CO., LTD. HANGZHOU S |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310004 HOUSE 5, BUILDING 9, NO.167, HUANCHENG NORTH ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 571127 GUILINYANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, MEILAN DISTRICT, HAIKOU CITY, HAINAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100707 Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Co-patentee after: Zhejiang Ruida Pharmaceutical Co.,Ltd. Patentee after: Hainan Poly Pharm Co.,Ltd. Co-patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 5, No. 9, building 167, building 310004, Ring North Road, Hangzhou, Zhejiang Patentee before: Fan Minhua |
|
| CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Zhejiang Ruida Pharm Co.,Ltd. False: Zhejiang Ruida Pharmaceutical Co.,Ltd. Number: 33 Volume: 26 |
|
| CI03 | Correction of invention patent |
Correction item: Patentee Correct: Zhejiang Ruida Pharm Co.,Ltd. False: Zhejiang Ruida Pharmaceutical Co.,Ltd. Number: 33 Page: The title page Volume: 26 |
|
| C56 | Change in the name or address of the patentee |
Owner name: HAINAN PLOY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN PULIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee before: Hainan Poly Pharm Co.,Ltd. Patentee before: Zhejiang Ruida Pharm Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221012 Address after: 571127 Guilin Ocean Economic Development Zone, Meilan District, Haikou City, Hainan Province Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Address before: 571127 Guilin Ocean Economic and Technological Development Zone, Meilan District, Haikou City, Hainan Province Patentee before: HAINAN POLY PHARM. Co.,Ltd. Patentee before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070926 |